These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Evaluating the rate of reversal of fentanyl-induced respiratory depression using a novel long-acting naloxone nanoparticle, cNLX-NP. Averick SE; Kassick AJ; Song D; Zhang B; Vigliaturo J; Luengas D; Silva-Ortiz P; Pravetoni M; Raleigh MD Front Psychiatry; 2024; 15():1366186. PubMed ID: 38550534 [TBL] [Abstract][Full Text] [Related]
10. Fact vs. fiction: naloxone in the treatment of opioid-induced respiratory depression in the current era of synthetic opioids. Dahan A; Franko TS; Carroll JW; Craig DS; Crow C; Galinkin JL; Garrity JC; Peterson J; Rausch DB Front Public Health; 2024; 12():1346109. PubMed ID: 38481848 [TBL] [Abstract][Full Text] [Related]
11. Opioid Antagonists from the Orvinol Series as Potential Reversal Agents for Opioid Overdose. Disney A; Olson KM; Shafer AM; Moore SC; Anand JP; Traynor JR; Husbands SM ACS Chem Neurosci; 2022 Nov; 13(21):3108-3117. PubMed ID: 36223082 [TBL] [Abstract][Full Text] [Related]
12. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic. Fairbairn N; Coffin PO; Walley AY Int J Drug Policy; 2017 Aug; 46():172-179. PubMed ID: 28687187 [TBL] [Abstract][Full Text] [Related]
13. Development of a Translational Model to Assess the Impact of Opioid Overdose and Naloxone Dosing on Respiratory Depression and Cardiac Arrest. Mann J; Samieegohar M; Chaturbedi A; Zirkle J; Han X; Ahmadi SF; Eshleman A; Janowsky A; Wolfrum K; Swanson T; Bloom S; Dahan A; Olofsen E; Florian J; Strauss DG; Li Z Clin Pharmacol Ther; 2022 Nov; 112(5):1020-1032. PubMed ID: 35766413 [TBL] [Abstract][Full Text] [Related]
14. Studies on the abstinence-like overshoot following reversal of the potent 19-isoamyl derivative of etorphine with naloxone. A comparison with the opioids fentanyl and alfentanil. Freye E; Neruda B; Smith OW Arzneimittelforschung; 1997 Jan; 47(1):6-9. PubMed ID: 9037435 [TBL] [Abstract][Full Text] [Related]
15. Binding preference at the μ-opioid receptor underlies distinct pharmacology of cyclopropyl versus valeryl analogs of fentanyl. Xie B; Le Rouzic VP; Goldberg A; Tsai MM; Chen L; Zhang T; Sinha A; Pan YX; Baumann MH; Shi L Neuropharmacology; 2023 Apr; 227():109442. PubMed ID: 36731721 [TBL] [Abstract][Full Text] [Related]
16. Treatment of opioid overdose: current approaches and recent advances. Britch SC; Walsh SL Psychopharmacology (Berl); 2022 Jul; 239(7):2063-2081. PubMed ID: 35385972 [TBL] [Abstract][Full Text] [Related]
17. Pharmacological Profiling of Antifentanyl Monoclonal Antibodies in Combination with Naloxone in Pre- and Postexposure Models of Fentanyl Toxicity. Baehr CA; Wu MM; Pandit SG; Arias-Umana J; AuCoin D; Pravetoni M J Pharmacol Exp Ther; 2022 May; 381(2):129-136. PubMed ID: 35153198 [TBL] [Abstract][Full Text] [Related]
18. New Psychoactive Substances and receding COVID-19 pandemic: really going back to "normal"? Napoletano S; Basile G; Lo Faro AF; Negro F Acta Biomed; 2022 May; 93(2):e2022186. PubMed ID: 35545997 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological evaluation and forensic case series of N-pyrrolidino etonitazene (etonitazepyne), a newly emerging 2-benzylbenzimidazole 'nitazene' synthetic opioid. Vandeputte MM; Krotulski AJ; Walther D; Glatfelter GC; Papsun D; Walton SE; Logan BK; Baumann MH; Stove CP Arch Toxicol; 2022 Jun; 96(6):1845-1863. PubMed ID: 35477798 [TBL] [Abstract][Full Text] [Related]